Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Gene–gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics

The Pharmacogenomics Journal volume 12, pages 54–61 (2012)Cite this article

Subjects

Abstract

The use of atypical antipsychotics (AAPs) is associated with increasing the risk of the metabolic syndrome (MetS), which is an important risk factor for cardiovascular disease and diabetes. Two insulin-induced gene (INSIG) isoforms, designated INSIG-1 and INSIG-2 encode two proteins that mediate feedback control of lipid metabolism. In this genetic case–control study, we investigated whether the common variants in INSIG1 and INSIG2 genes were associated with MetS in schizophrenic patients treated with atypical antipsychctics. The study included 456 schizophrenia patients treated with clozapine (n=171), olanzapine (n=91) and risperidone (n=194), for an average of 45.5±27.6 months. The prevalence of MetS among all subjects was 22.8% (104/456). Two single-nucleotide polymorphisms (SNPs) of the INSIG1 gene and seven SNPs of the INSIG2 gene were chosen as haplotype-tagging SNPs. In single-marker-based analysis, the INSIG2 rs11123469-C homozygous genotype was found to be more frequent in the patients with MetS than those without MetS (P=0.001). In addition, haplotype analysis showed that the C-C-C haplotype of rs11123469-rs10185316- rs1559509 of the INSIG2 gene significantly increased the risk of MetS (P=0.0023). No significant associations were found between polymorphisms of INSIG1 gene and MetS, however, INSIG1 and INSIG2 interactions were found in the significant 3-locus and 4-locus gene–gene interaction models (P=0.003 and 0.012, respectively). The results suggest that the INSIG2 gene may be associated with MetS in patients treated with AAPs independently or in an interactive manner with INSIG1.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. DE Hert M, Schreurs V, Vancampfort D, VAN Winkel R . Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009; 8: 15–22.

    Article  Google Scholar 

  2. Meyer JM, Stahl SM . The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009; 119: 4–14.

    Article  CAS  Google Scholar 

  3. Newcomer JW . Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007; 68 (Suppl 4): 8–13.

    PubMed  Google Scholar 

  4. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008; 101: 295–303.

    Article  Google Scholar 

  5. Medved V, Kuzman MR, Jovanovic N, Grubisin J, Kuzman T . Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up. J Psychopharmacol 2009; 23: 915–922.

    Article  CAS  Google Scholar 

  6. Correll CU, Frederickson AM, Kane JM, Manu P . Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 2008; 10: 788–797.

    Article  Google Scholar 

  7. Correll CU, Frederickson AM, Kane JM, Manu P . Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007; 89: 91–100.

    Article  Google Scholar 

  8. Bai YM, Chen TT, Yang WS, Chi YC, Lin CC, Liou YJ et al. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr Res 2009; 111: 1–8.

    Article  Google Scholar 

  9. Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006; 163: 1273–1276.

    Article  Google Scholar 

  10. Tsai SJ, Hong CJ . Pharmacogenetic studies of psychotropic drug-induced adverse effects. Current Pharmacogenomics 2005; 3: 157–164.

    Article  CAS  Google Scholar 

  11. Mulder H, Franke B, van der-Beek van der AA, Arends J, Wilmink FW, Scheffer H et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol 2007; 27: 338–343.

    Article  CAS  Google Scholar 

  12. Mulder H, Cohen D, Scheffer H, Gispen-de Wied C, Arends J, Wilmink FW et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psychopharmacol 2009; 29: 16–20.

    Article  CAS  Google Scholar 

  13. Ellingrod VL, Miller del D, Taylor SF, Moline J, Holman T, Kerr J . Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res 2008; 98: 47–54.

    Article  Google Scholar 

  14. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R et al. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 2002; 110: 489–500.

    Article  CAS  Google Scholar 

  15. Yabe D, Brown MS, Goldstein JL . Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proc Natl Acad Sci USA 2002; 99: 12753–12758.

    Article  CAS  Google Scholar 

  16. Cervino AC, Li G, Edwards S, Zhu J, Laurie C, Tokiwa G et al. Integrating QTL and high-density SNP analyses in mice to identify Insig2 as a susceptibility gene for plasma cholesterol levels. Genomics 2005; 86: 505–517.

    Article  CAS  Google Scholar 

  17. Liu JP . New functions of cholesterol binding proteins. Mol Cell Endocrinol 2009; 303: 1–6.

    Article  CAS  Google Scholar 

  18. Herbert A, Gerry NP, McQueen MB, Heid IM, Pfeufer A, Illig T et al. A common genetic variant is associated with adult and childhood obesity. Science 2006; 312: 279–283.

    Article  CAS  Google Scholar 

  19. Skelly T, Pinheiro AP, Lange LA, Sullivan PF . Is rs7566605, a SNP near INSIG2, associated with body mass in a randomized clinical trial of antipsychotics in schizophrenia? Mol Psychiatry 2007; 12: 321–322.

    Article  CAS  Google Scholar 

  20. Le Hellard S, Theisen FM, Haberhausen M, Raeder MB, Fernø J, Gebhardt S et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-r-lated metabolic adverse effects? Mol Psychiatry 2009; 14: 308–317.

    Article  CAS  Google Scholar 

  21. Lou XY, Chen GB, Yan L, Ma MJZ, Zhu J, Elston RC et al. A g neralized combinatorial approach for retecting gene-by-gene and gene-by-environment i t-ractions withtapplication to nicotine d pendence. Am J Hum Genet 2007; 80: 1125–1137.

    Article  CAS  Google Scholar 

  22. American Psychiatric Association 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). American Psychiatric Association: Washington, DC.

  23. Dudbridge F . Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered 2008; 66: 87–98.

    Article  Google Scholar 

  24. Storey JD . A direct approach to false discovery rate. J R Statist Soc B 2002; 64: 479.

    Article  Google Scholar 

  25. Fernø J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ et al. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J 2005; 5: 298–304.

    Article  Google Scholar 

  26. Raeder MB, Fernø J, Vik-Mo AO, Steen VM . SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects? Mol Cell Biochem 2006; 289: 167–173.

    Article  CAS  Google Scholar 

  27. Fernø J, Vik-Mo AO, Jassim G, Håvik B, Berge K, Skrede S et al. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology 2009; 203: 73–84.

    Article  Google Scholar 

  28. Engelking LJ, Liang G, Hammer RE, Takaishi K, Kuriyama H, Evers BM et al. Schoenheimer effect explained—feedback regulation of cholesterol synthesis in mice mediated by Insig proteins. J Clin Invest 2005; 115: 2489–2498.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grant V98C1–061, V98C1-055 from Taipei Veterans General Hospital, Taiwan, and grants NSC 95-2314-B-075 –011 and NSC 97-2314-B-075-001-MY3 from National Science Council Grant, Taiwan. The authors also thank Jer-Yuan Wu, the National Genomic Center and the National Clinical Core at Academia Sinica, Taiwan, for genotyping support.

Author information

Author notes

  1. Y-J Liou and Y M Bai: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan

    Y-J Liou, Y M Bai, C-J Hong & S-J Tsai

  2. Division of Psychiatry, School of Medicine, National Yang-Ming University, Taipei, Taiwan

    Y-J Liou, Y M Bai, C-J Hong & S-J Tsai

  3. Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan

    Y-J Liou

  4. Vita Genomics, Taipei, Taiwan

    E Lin

  5. Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan

    E Lin

  6. Department of Psychiatry, Yuli Veterans Hospital, Yuli, Hualien, Taiwan

    J-Y Chen & T-T Chen

  7. Institute of Brain Science, National Yang-Ming University, Taipei, Taiwan

    C-J Hong

Authors
  1. Y-J Liou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y M Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J-Y Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T-T Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C-J Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S-J Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to C-J Hong or S-J Tsai.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liou, YJ., Bai, Y., Lin, E. et al. Gene–gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Pharmacogenomics J 12, 54–61 (2012). https://doi.org/10.1038/tpj.2010.74

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2010.74

Keywords

This article is cited by

Search

Advanced search

Quick links